All monetary amounts are expressed in Canadian Dollars, unless otherwise indicated. IsoEnergy Ltd. is pleased to announce that it has closed its previously announced bought deal financing, pursuant to ...

Understanding the numbers behind the news is the focus of this year’s Boulder Chamber Forecast, featuring analyses by University of Colorado economists and the state demographer.

Behavioral economics, like “lived experience,” existed long before anyone thought a special and seemingly redundant name was required. To Adam Smith, economics was made of human behavior in all its ...

Today on a special edition of Flashpoints: Radical Economist and economic visionary Richard Wolff is joined by Dr. Harriet Fraad and Professor Shahram Azhar to discuss the results of the 2024 ...

Richard Whitman has received funding from the Economic and Research Council of the UK as a Senior Fellow of the UK in a Changing Europe initiative. He is a past recipient of grant funding from the ...

CytoAgents, Inc. a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation, announced today the appointment of Dr. Johannes ...

Mere weeks after being named the nation’s top drug regulator, Richard Pazdur, M.D., is taking steps to retire as head of the FDA’s Center for Drug Evaluation and Research (CDER), an FDA spokesperson ...

This week, Richard Waters, FT columnist and former West Coast editor, talks with MIT Technology Review’s editor at large David Rotman about the true impact of AI on the job market. Welcome back to The ...

"Grey’s Anatomy" veteran James Pickens Jr. is opening up about his own real-life health diagnosis. Following the Thursday, Nov. 13 midseason finale episode, ABC aired a public service announcement ...

In a surprise move, the FDA has named the longtime leader of its oncology department, Richard Pazdur, M.D., as the new director of the Center for Drug Evaluation and Research, which oversees most ...

Dr. Richard Pazdur, who has been the F.D.A.’s top cancer drug regulator, represents a stabilizing choice for an agency reeling under staff cuts and low morale. By Christina Jewett and Rebecca Robbins ...